National University of Singapore (NUS; 新加坡国立大学) is a public research university in Singapore offering undergraduate and graduate education across science, engineering, medicine, computing, and the social sciences. It operates a broad network of faculties, schools, and research institutes, and engages in fundamental and applied research.
For the chemical and life-sciences ecosystem, NUS conducts research in chemistry, chemical and biomolecular engineering, materials science, catalysis, drug discovery, energy, and sustainability. The university collaborates with hospitals, government agencies, and industry partners, and supports technology transfer through licensing and spin-offs. Its researchers contribute to developments spanning pharmaceuticals and biologics, polymers and advanced materials, process engineering, and environmental technologies.
Also known as 新加坡国立大学.
Dual Ang‑2/VEGF‑A inhibitor delivered vision gains, lesion regression and dosing intervals up to 20 weeks for most patients in a two‑year Asian PCV trial.
Partner will lead clinical development, manufacturing and global commercialization of AID351, an anti‑dengue antibody active across four serotypes; originators retain royalty and sublicence share.
BI 765423, targeting IL-11, enters Phase IIa trials for IPF, aiming to improve lung function. Pre-clinical studies show promise in halting fibrosis and restoring lung functionality.
